Search Results - "Kappeler, D."

  • Showing 1 - 13 results of 13
Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7

    Ensuring Patient Safety and Data Integrity in Clinical Trials for the Treatment of Bronchiolitis Obliterans Syndrome (BOS) during the COVID-19 Pandemic by Fernandes, S. Prante, Hagedorn, T., Salerio, I., Cuomo, D., Kappeler, D., Tutone, M., Witte, S., Vaja, V.

    “…The current COVID-19 pandemic has posed challenges to the conduct of clinical trials. BOSTON-1 and BOSTON-2 are two ongoing phase III, prospective,…”
    Get full text
    Journal Article
  8. 8

    Liposomal Cyclosporine A (L-CsA) via Inhalation to Treat Bronchiolitis Obliterans Syndrome: Novel Formulation and Drug-Specific Delivery System Improves Tolerability by Henig, N., Teichmann, J., Paulukat, J., Kappeler, D., Denk, O., Boerner, G.

    “…Bronchiolitis obliterans syndrome (BOS) is the major obstacle to long-term benefit after lung transplantation. There is no therapy with demonstrated benefit…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11

    Macroprolactinaemia, the major unknown in the differential diagnosis of hyperprolactinaemia by Cattaneo, F, Kappeler, D, Müller, B

    Published in Swiss medical weekly (10-03-2001)
    “…We report on 10 cases of macroprolactinaemia and discuss recent evidence that many patients with hyperprolactinaemia (8-26%, depending on the population…”
    Get full text
    Journal Article
  12. 12
  13. 13